Company: PED
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003703
Chunk: 622

Company: PEDEVCO CORP
Filing Date: 2025-03-31
Form: 10-K
Item: Item 12
Chunk 622
---
 of which Dr. Kukes is the trustee and beneficiary, and as such, Dr. Kukes is deemed to be the beneficial owner of the shares held by The SGK 2018 Revocable Trust.

 141Table of Contents

Equity Compensation Plan Information

The following table sets forth information, as of December 31, 2024, with respect to our compensation plans under which common stock is authorized for issuance. 

Plan Category  Number of securities to be issued upon exercise of outstanding options, warrants and rights(A)   Weighted-average exercise price of outstanding options, warrants and rights(B)   Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in Column A)(C) Equity compensation plans approved by stockholders (1)  1,835,667  $1.12   6,545,000(2)Equity compensation plans not approved by stockholders  -       - Total  1,835,667  $1.12   6,545,000 

(1)Consists of options to purchase 525,667 shares of common stock issued and outstanding under the PEDEVCO Corp. 2012 Amended and Restated Equity Incentive Plan and options to purchase 1,310,000 shares of common stock issued and outstanding under the PEDEVCO 2021 Equity Incentive Plan.

(2)Consists of 6,545,000 shares of common stock reserved and available for issuance under the PEDEVCO Corp. 2021 Equity Incentive Plan. Does not include shares of common stock available for issuance under the 2012 Plan or 2012 Pre-Merger Plan as the Company has determined that it can no longer issue awards thereunder.

The Company’s equity compensation plans are discussed in greater detail above under “Item 11. Executive Compensation” - “Equity Incentive Plans”.

Changes in Control

The Company is not currently aware of any arrangements which may at a subsequent date result in a change of control of the Company.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

Except as referenced below or otherwise disclosed above under “Item 11. Executive Compensation”, which information is incorporated by reference in this Item 13, there have been no transactions since January 1, 2023, and there is not currently any proposed transaction, in which the Company